Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ERGO (fights fat, diabetes II, and Heart disease) -- Ignore unavailable to you. Want to Upgrade?

To: fordor who wrote (94)	11/23/1998 3:01:00 PM
From: Codee	Read Replies (1) \| Respond to of 110

what is the time frame for down the road...

To: fordor who wrote (94)	11/24/1998 1:16:00 PM
From: tommysdad	Read Replies (1) \| Respond to of 110

Great buy? Better news? Based on what? I'm sorry, I don't see it. Appeals to the FDA very seldom win. Ergo has bromocryptine, and that's it. The odds against approval at this point are incredibly high. The clinicals are not compelling, they don't know the mechanism of action, it's a re-formulation of a very old drug. Let's say Ergoset beats the odds and gets approval -- who's going to prescribe the stuff at this point? The opportunity to average down on this stock has only just begun. You may see a pop here and there, or a dead cat bounce, but without Ergoset there is no reason to own Ergo. Period. Don't tell me J & J wouldn't buy in to a dog -- J & J also partnered with Amylin. Diabetes is a very complex disease and has claimed yet another biotech (AMLN, ALTN, now ERGO).